TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signaling.
Fiche publication
Date publication
mars 2020
Journal
The European respiratory journal
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Dr DEMIDOV Oleg, Dr BELLAYE Pierre-Simon, Pr BONNIAUD Philippe, Dr BELTRAMO Guillaume
Tous les auteurs :
Boutanquoi PM, Burgy O, Beltramo G, Bellaye PS, Dondaine L, Marcion G, Pommerolle L, Vadel A, Spanjaard M, Demidov O, Mailleux A, Crestani B, Kolb M, Garrido C, Goirand F, Bonniaud P
Lien Pubmed
Résumé
Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterised by myofibroblast proliferation and abnormal extracellular matrix (ECM) accumulation in the lungs. Transforming-growth-factor (TGF)-β1 initiates key profibrotic signaling involving the SMADs pathway and the small heat shock protein αB-crystallin (HSPB5). TRIpartite Motif-containing 33 (TRIM33) has been reported to negatively regulate TGF-β/SMADs signaling but its role in fibrogenesis remains unknown.
Référence
Eur. Respir. J.. 2020 Mar 17;: